Mishra Sumita, Dunkerly-Eyring Brittany L, Keceli Gizem, Ranek Mark J
Division of Cardiology, Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD, United States.
Department of Pharmacology and Molecular Sciences, Johns Hopkins University, Baltimore, MD, United States.
Front Physiol. 2020 Nov 12;11:593585. doi: 10.3389/fphys.2020.593585. eCollection 2020.
Many forms of cardiac disease, including heart failure, present with inadequate protein quality control (PQC). Pathological conditions often involve impaired removal of terminally misfolded proteins. This results in the formation of large protein aggregates, which further reduce cellular viability and cardiac function. Cardiomyocytes have an intricately collaborative PQC system to minimize cellular proteotoxicity. Increased expression of chaperones or enhanced clearance of misfolded proteins either by the proteasome or lysosome has been demonstrated to attenuate disease pathogenesis, whereas reduced PQC exacerbates pathogenesis. Recent studies have revealed that phosphorylation of key proteins has a potent regulatory role, both promoting and hindering the PQC machinery. This review highlights the recent advances in phosphorylations regulating PQC, the impact in cardiac pathology, and the therapeutic opportunities presented by harnessing these modifications.
包括心力衰竭在内的多种心脏病形式都存在蛋白质质量控制(PQC)不足的情况。病理状况通常涉及终末错误折叠蛋白质的清除受损。这会导致形成大的蛋白质聚集体,进而进一步降低细胞活力和心脏功能。心肌细胞拥有一个复杂协作的PQC系统,以将细胞蛋白毒性降至最低。伴侣蛋白表达增加或蛋白酶体或溶酶体对错误折叠蛋白质清除的增强已被证明可减轻疾病发病机制,而PQC降低则会加剧发病机制。最近的研究表明,关键蛋白的磷酸化具有强大的调节作用,既促进又阻碍PQC机制。本综述重点介绍了磷酸化调节PQC的最新进展、对心脏病理学的影响以及利用这些修饰所带来的治疗机会。